Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SillaJen, Inc.
Washington University School of Medicine
Dana-Farber Cancer Institute
AstraZeneca
Nurix Therapeutics, Inc.
M.D. Anderson Cancer Center
Light Chain Bioscience - Novimmune SA
Vanderbilt-Ingram Cancer Center
QuantumLeap Healthcare Collaborative
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Calithera Biosciences, Inc
Boston Pharmaceuticals
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)